leadf
logo-loader
viewAustral Gold Limited

Austral Gold acquires interest in Chilean mining services provider

au_chile__350_538d289c90d40.jpg

Austral Gold (ASX:AGD) has acquired a controlling 51% stake in Chilean mining services provider Humberto Reyes Arriendo de Maquinarias SpA (Humberto Reyes) for US$2.7 million.

Humberto Reyes has been undertaking underground contract mining at the company’s Guanaco mine since 2011.

It owns mining equipment and associated vehicles with a book value of US$4 million.

The transaction is expected to deliver important annualised savings to the Guanaco mine, which produces over 4,000 gold equivalent ounces per month.

It also provides flexibility to accelerate mining of the Guanaco mine resource; allows greater control over safety and production practices at the Guanaco mine; ensures a continued competitive cost for future underground development; and grants greater control over the Guanaco mine operations.

Austral will make an initial upfront payment of US$450,000 and the remainder in monthly cash instalments over three years from existing cash reserves.

It also has an option to acquire the remaining 49% in 2.5 years at a price to be agreed upon by both parties.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Austral Gold Limited

Price: 0.23 AUD

ASX:AGD
Market: ASX
Market Cap: $130.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharma updates on ArtemiC coronavirus study and first-ever THC shipment...

MGC Pharmaceuticals Ltd's (ASX:MXC) Roby Zomer speaks to Proactive's Andrew Scott soon after announcing positive results from a pre-clinical study of ArtemiCTM on rats with no pathological changes or differences between the study groups reported. He also discusses its first-ever shipments of the...

3 hours, 6 minutes ago

2 min read